Protection against vaccine preventable diseases in children treated for acute lymphoblastic leukemia
Authors:
- 8 October 2016
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 64 (2) , 315-320
Abstract
The objective of this retrospective study was to assess protection against vaccine preventable diseases (VPDs) in children treated for acute lymphoblastic leukemia (ALL). Clinical characteristics and vaccination records were collected. Antibodies against VPDs were measured after completion of chemotherapy and after a booster dose of vaccine. Immunization status of household members was evaluated. Sixty children were included. Median interval between the end of chemotherapy and enrolment in the study was 13 months (range 1–145). At ALL diagnosis, 81.3% of the children were up to date with their vaccination schedule. This proportion decreased to 52.9% at enrolment. Among the parents, 21% were up to date with their immunization schedule and 42% had received seasonal influenza vaccination. After chemotherapy, less than 50% of the patients were seroprotected against tetanus, diphtheria, polio 3, Haemophilus influenzae type b (Hib), and mumps and no more than 80% were seroprotected against polio 1 and 2, measles, rubella, and varicella. After a booster dose of vaccine, the rate of protection increased to over 90% for each of the following antigens: TT, DT, polio 1, Hib, measles, and rubella. Nevertheless, polio 3, mumps, and varicella-zoster virus antibodies titers/concentrations remained below seroprotective thresholds in over 20% of the patients. After chemotherapy for ALL, most of the children were not protected against VPDs. As the majority mounted a robust response to booster vaccines, efforts need to be done to improve protection against VPDs by implementing a systematic vaccine booster schedule. This could also be helped by reinforcing household members’ immunization.Keywords
This publication has 27 references indexed in Scilit:
- Survival improvement by decade of patients aged 0–14 years with acute lymphoblastic leukemia: a SEER analysisScientific Reports, 2014
- Contagious Comments: What Was the Online Buzz About the 2011 Quebec Measles Outbreak?PLOS ONE, 2013
- Measles Elimination Efforts and 2008–2011 Outbreak, FranceEmerging Infectious Diseases, 2013
- Correlates of Protection Induced by VaccinationClinical and Vaccine Immunology, 2010
- Impact of influenza-like illness and effectiveness of influenza vaccination in oncohematological children who have completed cancer therapyVaccine, 2010
- Safety and immunogenicity of a hexavalent diphtheria–tetanus–acellular pertussis–inactivated poliovirus–Haemophilus influenzae b conjugate–hepatitis B vaccine at 2, 3, 4, and 12–14 months of ageVaccine, 2009
- Immunisation practices of paediatric oncologists: An Australasian surveyJournal of Paediatrics and Child Health, 2007
- Increased risk for invasive pneumococcal diseases in children with acute lymphoblastic leukaemiaBritish Journal of Haematology, 2007
- Reimmunization after Therapy for Childhood CancerClinical Infectious Diseases, 2007
- Risk of Haemophilus influenzae Type b Disease in Children with Cancer and Response of Immunocompromised Leukemic Children to a Conjugate VaccineThe Journal of Infectious Diseases, 1990